197 related articles for article (PubMed ID: 31782939)
1. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study.
Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T
Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939
[No Abstract] [Full Text] [Related]
2. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety.
Christensen B; Colman RJ; Micic D; Gibson PR; Goeppinger SR; Yarur A; Weber CR; Cohen RD; Rubin DT
Inflamm Bowel Dis; 2018 Mar; 24(4):849-860. PubMed ID: 29562271
[TBL] [Abstract][Full Text] [Related]
3. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
Allegretti JR; Barnes EL; Stevens B; Storm M; Ananthakrishnan A; Yajnik V; Korzenik J
Dig Dis Sci; 2017 Jun; 62(6):1590-1596. PubMed ID: 28357697
[TBL] [Abstract][Full Text] [Related]
5. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Faleck DM; Winters A; Chablaney S; Shashi P; Meserve J; Weiss A; Aniwan S; Koliani-Pace JL; Kochhar G; Boland BS; Singh S; Hirten R; Shmidt E; Kesar V; Lasch K; Luo M; Bohm M; Varma S; Fischer M; Hudesman D; Chang S; Lukin D; Sultan K; Swaminath A; Gupta N; Siegel CA; Shen B; Sandborn WJ; Kane S; Loftus EV; Sands BE; Colombel JF; Dulai PS; Ungaro R
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2497-2505.e1. PubMed ID: 30625408
[TBL] [Abstract][Full Text] [Related]
6. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study.
Adar T; Faleck D; Sasidharan S; Cushing K; Borren NZ; Nalagatla N; Ungaro R; Sy W; Owen SC; Patel A; Cohen BL; Ananthakrishnan AN
Aliment Pharmacol Ther; 2019 Apr; 49(7):873-879. PubMed ID: 30773667
[TBL] [Abstract][Full Text] [Related]
7. The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
Abraham BP; Fan C; Thurston T; Moskow J; Malaty HM
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004241
[TBL] [Abstract][Full Text] [Related]
8. Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.
Lin WC; Tai WC; Chang CH; Tu CH; Feng IC; Shieh MJ; Chung CS; Yen HH; Chou JW; Wong JM; Liu YH; Huang TY; Chuang CH; Tsai TJ; Chiang FF; Lu CY; Hsu WH; Yu FJ; Chao TH; Wu DC; Ho AS; Lin HH; Feng CL; Wu KL; Wong MW; Tung CC; Lin CC; Chen CC; Hu HM; Lu LS; Wang HS; Wu IC; Kuo HY; Wu JF; Yao Shih H; Ni YH; Tang SL; Chen PH; Wei SC
Inflamm Bowel Dis; 2023 Nov; 29(11):1730-1740. PubMed ID: 36626567
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Ferrante M; Jordi Guardiola ; Jahnsen J; Louis E; Lukáš M; Reinisch W; Roblin X; Smith PJ; Kwon T; Kim J; Yoon S; Kim DH; Atreya R
BMC Gastroenterol; 2024 Mar; 24(1):121. PubMed ID: 38539103
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
11. Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
Ungaro RC; Kadali H; Zhang W; Adsul S; Reinisch W
J Crohns Colitis; 2023 Dec; 17(12):1949-1961. PubMed ID: 37492976
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
Schreiber S; Dignass A; Peyrin-Biroulet L; Hather G; Demuth D; Mosli M; Curtis R; Khalid JM; Loftus EV
J Gastroenterol; 2018 Sep; 53(9):1048-1064. PubMed ID: 29869016
[TBL] [Abstract][Full Text] [Related]
13. In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab.
Loly JP; Vieujean S; Reenaers C; Van Kemseke C; Seidel ScD L; Louis E; Somja J
Inflamm Bowel Dis; 2024 Feb; 30(2):240-246. PubMed ID: 37042951
[TBL] [Abstract][Full Text] [Related]
14. Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients.
Cicala M; Gori M; Balestrieri P; Altomare A; Tullio A; Di Cola S; Dejongh S; Graziani MG; Pagnini C; Carotti S; Perrone G; Ribolsi M; Fiorani M; Guarino MPL; Farré R
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892004
[TBL] [Abstract][Full Text] [Related]
15. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
Kim K; Park JJ; Yoon H; Lee J; Kim KO; Kim ES; Kim SY; Boo SJ; Jung Y; Yoo JH; Hwang SW; Park SH; Yang SK; Ye BD;
Aliment Pharmacol Ther; 2024 Jun; 59(12):1539-1550. PubMed ID: 38616380
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis.
Battat R; Dulai PS; Vande Casteele N; Evans E; Hester KD; Webster E; Jain A; Proudfoot JA; Mairalles A; Neill J; Singh S; Chang JT; Rivera-Nieves J; Sandborn WJ; Boland BS
Inflamm Bowel Dis; 2019 Jan; 25(2):410-420. PubMed ID: 30295781
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.
Ansari M; Glassner K; Irani M; Saleh A; Wang L; Ezeana C; Wong S; Perry C; Abraham B
J Dig Dis; 2024 Feb; 25(2):91-99. PubMed ID: 38599667
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies.
Macaluso FS; Ventimiglia M; Orlando A
J Crohns Colitis; 2023 Aug; 17(8):1217-1227. PubMed ID: 36913311
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Sandborn WJ; Dornic Q; Lindner D; Kisfalvi K; Marins EG; Vermeire S
Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):404-415. PubMed ID: 38417060
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
Alrashed F; Abdullah I; Alfadhli A; Shehab M
Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
[No Abstract] [Full Text] [Related]
[Next] [New Search]
